Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation

Haematologica

Volumn 86, Issue 4, 2001, Pages 409-413

  Tosi, P ^a   Ronconi, S ^a   Zamagni, E ^a   Cellini, C ^a   Grafone, T ^a   Cangini, D ^a   Pileri, S A ^a   Baccarani, M ^a   Tura, S ^a   Cavo, M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Autologous stem cell transplantation; Multiple myeloma; Thalidomide

Indexed keywords

PARAPROTEIN; THALIDOMIDE;

ADULT; ARTICLE; BLOOD AUTOTRANSFUSION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; DRUG INDICATION; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; LETHARGY; LEUKOPENIA; MALE; MULTIPLE MYELOMA; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; ANGIOGENESIS INHIBITORS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; SALVAGE THERAPY; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0035024063     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Plasma cell dyscrasias
2. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
3. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma
4. High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma
5. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?
6. High-dose chemotherapy with carboplatin, cyclophosphamide and etoposide and autologous transplantation for multiple myeloma relapsing after a previous transplant
7. Antitumor activity of thalidomide in refractory multiple myeloma
8. Therapy with thalidomide in refractory multiple myeloma patients-the revival of an old drug
9. Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent
10. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional chemotherapy
11. Low-dose of thalidomide in the treatment of refractory myeloma
12. VAD-based regimens as primary treatment for multiple myeloma
13. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma
14. Proposed guidelines for protocol studies. II. Plasma cell myeloma
15. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
16. + cells in the peripheral blood
17. Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection
18. Effects of thalidomide on HIV-associated wasting syndrome: A randomized, double blind, placebo-controlled clinical trial
19. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: Experience in sixteen consecutive patients
20. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide
21. Thalidomide treatment for chronic graft-versus-host disease
22. Thalidomide for the treatment of chronic graft-versus-host disease
23. Thalidomide as salvage therapy for chronic graft-versus-host disease
24. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes
25. + subset
26. Inhibition of IL-12 production by thalidomide
27. Thalidomide is an inhibitor of angiogenesis
28. Multiple myeloma: Increasing evidence for a multistep transformation process
29. What is the evidence that tumors are angiogenesis dependent?
30. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
31. Low-dose thalidomide seems to be effective in multiple myeloma
32. Thalidomide and dexamethasone as salvage therapy for refractory and relapsed myeloma
33. Thalidomide and dexamethasone combination for multiple myeloma refractory to dexamethasone-based regimens